Research programme: therapeutic agents - Whanin Pharmaceuticals

Drug Profile

Research programme: therapeutic agents - Whanin Pharmaceuticals

Alternative Names: WIB-1001C; WIB-801C; WIB-901H; WIN-1001X; WIN-902A; WIP-901; WIP-901C

Latest Information Update: 06 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Whanin Pharmaceutical
  • Class
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Obesity; Stroke
  • Research Dementia; Hepatitis C
  • Discontinued Hyperlipidaemia; Neurodegenerative disorders; Osteoarthritis

Most Recent Events

  • 06 Oct 2016 WIB 1001C is still in research development for Dementia in South Korea (Whanin Pharmaceuticals pipeline, October 2016)
  • 06 Oct 2016 WIB 801C is still in preclinical development for Stroke in South Korea (Whanin Pharmaceuticals pipeline, October 2016)
  • 06 Oct 2016 WIN 902A is still in preclinical development for Obesity in South Korea (Whanin Pharmaceuticals pipeline, October 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top